BRD2 and colorectal carcinoma: AD-NAT and CRC-NAT specimens (76.0 ± 2.1%, 76.4 ± 2.0%, respectively) showed significantly reduced methylation levels compared to the samples of healthy individuals (77.5 ± 1.7%) (p ≤ 0.05) (Additional file 2/A).